<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031351</url>
  </required_header>
  <id_info>
    <org_study_id>032-2017</org_study_id>
    <nct_id>NCT05031351</nct_id>
  </id_info>
  <brief_title>NF-κB Inhibition in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>NIALS</acronym>
  <official_title>Nuclear Factor Kappa Beta Inhibition in Patients With Amyotrophic Lateral Sclerosis: A Phase II Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled&#xD;
      clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic&#xD;
      Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be up to 75 participants randomized 1:1:1 to receive either high dosage Withania&#xD;
      somnifera extract (1088 mg daily), medium dosage Withania somnifera extract (544 mg daily) or&#xD;
      matching placebo. The study will consist of a Screening Period, Randomization visit, Baseline&#xD;
      visit, and Follow-up visits. The treatment period will be 8 weeks and a final follow up call&#xD;
      will occur at Week 9.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (safety)</measure>
    <time_frame>From Baseline visit until end of study visit (Week 9)</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SICI values</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RMT values</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Resting motor threshold (RMT) measured by transcranial magnetic stimulation (TMS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Electrotonus</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>This is a lower motor neuron excitability parameter measured by threshold tracking nerve excitability testing (NET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in recovery cycle</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>This is a lower motor neuron excitability parameter measured by threshold tracking nerve excitability testing (NET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in strength duration time constant</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>This is a lower motor neuron excitability parameter measured by threshold tracking nerve excitability testing (NET).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incident cases of ALSFRS-R score changes of 4 or more points</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Any incident case of ≥ 4-point increase in the ALS Functional Rating Scale-Revised (ALSFRS-R) scores or significant clinical improvement at week 8 will be reported. Changes in pro-inflammatory tests (CRP and IL-6) from baseline to Week 8 will be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum IL-6 levels</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Serum IL-6 levels will serve as an indirect marker of NF-kB inhibition and target engagement.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>High dosage Withania somnifera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>544mg oral twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage Withania somnifera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>272mg oral twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched capsules twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Withania somnifera</intervention_name>
    <description>Nuclear Factor Kappa Beta Inhibitor</description>
    <arm_group_label>High dosage Withania somnifera</arm_group_label>
    <arm_group_label>Medium dosage Withania somnifera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with laboratory supported probable, clinically possible, probable or&#xD;
             definite ALS according to the World Federation of Neurology Revised El Escorial&#xD;
             criteria (83) (Appendix A)&#xD;
&#xD;
          -  Disease duration from symptom onset no greater than 36 months at the Screening Visit&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Capable of providing informed consent and complying with study procedures&#xD;
&#xD;
          -  If taking riluzole, on a stable dose for at least 30 days prior to Screening Visit&#xD;
&#xD;
          -  If taking edaravone, on a stable dose for at least one cycle prior to Screening Visit&#xD;
&#xD;
          -  If on BiPAP, average usage of no more than 12 hours per day at time of Screening Visit&#xD;
&#xD;
          -  Able to swallow a capsule at Baseline Visit&#xD;
&#xD;
          -  Fluency in English or French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to any investigational agent or Withania somnifera (Ashwagandha) within 30&#xD;
             days prior to the Screening Visit; simultaneous participation in other observational&#xD;
             studies is allowed upon Site Investigator approval&#xD;
&#xD;
          -  Presence of any of the following clinical conditions:&#xD;
&#xD;
               1. Substance abuse within the past year&#xD;
&#xD;
               2. Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active&#xD;
                  malignancy or infectious disease&#xD;
&#xD;
               3. Acquired Immunodeficiency Syndrome (AIDS) or AIDS-related complex&#xD;
&#xD;
               4. Unstable psychiatric illness defined as psychosis (hallucinations or delusions)&#xD;
                  or untreated major depression within 90 days prior to the Screening Visit&#xD;
&#xD;
          -  Hypersensitivity or allergy to Withania somnifera&#xD;
&#xD;
          -  Uncontrolled diabetes with severe associated complications (such as neuropathy)&#xD;
&#xD;
          -  Untreated hypertension, active stomach ulcers, or untreated thyroid disorder&#xD;
&#xD;
          -  Previously diagnosed auto-immune condition with or without neurological manifestations&#xD;
             (e.g. multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid&#xD;
             arthritis, etc.)&#xD;
&#xD;
          -  Current or planned use of oral, intramuscular or intravenous steroid drugs (such as&#xD;
             prednisone, prednisolone, dexamethasone, triamcinolone, methylprednisolone,&#xD;
             oxandrolone, and others) or immunosuppressant drugs (azathioprine, mycophenolate,&#xD;
             tacrolimus, sirolimus, cyclophosphamide, and others) for more than 7 days&#xD;
&#xD;
          -  Planned consumption of alcohol, other drugs or natural health products with sedative&#xD;
             and anxiolytics properties while taking study drugs (8 week duration)&#xD;
&#xD;
          -  Current or planned use of continuous subcutaneous, intravenous or oral anticoagulant&#xD;
             drugs&#xD;
&#xD;
          -  Scheduled for surgery under general anesthetic within 14 days of Screening Visit&#xD;
&#xD;
          -  Pregnancy or planned pregnancy. Women of childbearing potential must have a negative&#xD;
             pregnancy test and be non-lactating at the Screening Visit&#xD;
&#xD;
          -  Insertion of a diaphragm pacing system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agessandro Abrahao, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorne Zinman, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Sunnybrook Research Institute, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hajara Abdirahman</last_name>
    <phone>+1 (416)480-6860</phone>
    <email>hajara.abdirahman@sri.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shirley Pham</last_name>
    <phone>+1 (416)480-6860</phone>
    <email>shirley.pham@sunnybrook.ca</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Withania somnifera</keyword>
  <keyword>Ashwagandha</keyword>
  <keyword>Nuclear Factor Kappa Beta Inhibition</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

